For our next talk, in the BDI/CHG (gen)omics Seminar series, we will be hearing from Professor Georgia Chenevix-Trench, Distinguished Scientist, Head of Cancer Genetics at the Queensland Institute of Medical Research Berghofer Medical Research Institute, Brisbane, Australia, and Fellow of the Australian Academy of Sciences. We’re delighted to host Prof Chenevix-Trench in what promises to be a great talk!
Date: Thursday 11 July
Time: 9:30 – 10:30
Talk title: Follow up of breast cancer GWAS through drug repositioning and CRISPR screens
Location: Centre for Human Genetics, Seminar room B
Abstract:
Mostly through the efforts of the Breast Cancer Association Consortium, and the Consortium of Investigators or Modifiers of BRCA1/2, genome-wide association studies of breast cancer risk have identified over 200 risk loci. However, as with other complex traits, it is a challenge to move beyond GWAS to identifying the target tissues, genes and pathways. Part of the impetus for doing so, stems from the knowledge that the likelihood of a new drug progressing through the pipeline to approval, is greatly increased if it has genetic support. I will discuss two ‘post-GWAS’ projects a) functional CRISPR screens to identify putative breast cancer risk genes with relevant functions, and b) investigating repurposing a drug developed for sickle cell anemia for breast cancer prevention and treatment.
Bio:
Professor Georgia Chenevix-Trench is Distinguished Scientist at the Queensland Institute of Medical Research in Brisbane, Australia, and Fellow of the Australian Academy of Sciences. She is the author of more than 500 peer-reviewed papers, and has been instrumental in the collection of public resources such as kConFab, the Australian consortium for research into familial breast cancer. She founded the international Consortium of Investigators of Modifiers of BRCA1/2, and is a founding member of the Breast Cancer Association Consortium, which together have identified over 200 breast cancer susceptibility loci since the advent of genome-wide association studies. The major focus of her current research is to identify the target genes at these loci though functional CRISPR screens, and to identify opportunities for drug repositioning.
—————————————————————
All members of the University are welcome to join. We hope you can join us!
We also now have a mailing list –
To be added, ping genomics_bdi_whg-subscribe@maillist.ox.ac.uk (with any message), you should get a bounce-back with three options to confirm your subscription. Follow any of those options, and with a bit of luck you should be signed up!
As a reminder, the (gen)omics seminar series is intended to increase interaction between individuals working in genomics across Oxford. We encourage in-person attendance where possible. There is time for discussion over, tea, coffee and pastries after the talks.
Hybrid Option:
Please note that these meetings are closed meetings and only open to members of the University of Oxford to encourage sharing of new and unpublished data. Please respect our speakers and do not share the link with anyone outside of the university.
Microsoft Teams meeting –
Meeting ID: 395 271 358 549
Passcode: 66WxAj
———————————————————————————————————
If you wish to know more or receive information related to trainings and events at BDI, please subscribe by emailing bdi-announce-subscribe@maillist.ox.ac.uk. You’ll then receive an email from SYMPA and once you reply you’ll be on the list!
